The HAGH Knockout SK-HEP-1 Polyclonal Cells product features a CRISPR/Cas9-edited polyclonal population of SK-HEP-1 cells carrying targeted disruption of the HAGH gene. HAGH encodes hydroxyacylglutathione hydrolase, also known as glyoxalase II, which is essential for methylglyoxal detoxification. The polyclonal knockout format avoids the pitfalls of single-cell clonal variability, offering a more representative cellular model. This loss-of-function system is ideal for probing the glyoxalase pathway’s role in cancer and metabolic diseases.
SK-HEP-1 is a human liver adenocarcinoma cell line established from a pleural effusion of a patient with hepatic cancer. Despite early debates about its endothelial versus epithelial origin, it is now firmly utilized as a hepatocellular carcinoma model. SK-HEP-1 displays hepatic characteristics, including drug-metabolizing enzyme expression, making it valuable for hepatotoxicity, pharmacokinetics, and cancer metabolism research. This genetic background provides a relevant context to study HAGH function in liver cancer, where redox balance and metabolic detoxification are often dysregulated.
HAGH catalyzes the hydrolysis of S-D-lactoylglutathione to D-lactate and glutathione, completing the glyoxalase pathway that neutralizes the cytotoxic metabolite methylglyoxal. Methylglyoxal reacts with proteins and DNA to form advanced glycation end-products (AGEs), contributing to cellular damage. The glyoxalase pathway is initiated by glyoxalase I (GLO1), which uses glutathione as a cofactor to convert methylglyoxal to S-D-lactoylglutathione. HAGH action regenerates glutathione, thereby maintaining cellular redox balance. Transcriptional control of this pathway is mediated by NRF2, a key antioxidant transcription factor activated by oxidative stress. Thus, HAGH deficiency disrupts glutathione homeostasis, increases methylglyoxal accumulation, and sensitizes cells to AGE-related stress.
In the context of SK-HEP-1 hepatic adenocarcinoma, HAGH knockout enables the dissection of how glyoxalase activity intersects with cancer metabolism, drug metabolism, and oncogenic signaling. Methylglyoxal can play a dual role??inducing apoptosis at high levels while promoting cancer cell proliferation and metastasis under certain conditions. By abrogating HAGH, this model permits examination of glutathione-dependent drug resistance mechanisms, the impact of methylglyoxal-derived AGEs on tumor progression, and the contribution of NRF2-mediated antioxidant responses. It also serves as a tool for diabetic complication research, where aberrant methylglyoxal metabolism drives nephropathy and retinopathy.
Typical applications include glyoxalase activity assays, methylglyoxal and D-lactate quantification, and glutathione level measurements. Researchers can assess AGE formation under methylglyoxal challenge, perform cell viability and migration/invasion assays to evaluate stress responses, and use western blotting to confirm HAGH knockout. The model supports investigations into NRF2 signaling, drug resistance in liver adenocarcinoma, and the metabolic consequences of glyoxalase deficiency. For further details or to inquire about custom needs, please contact Ascent Research.
